Johnson & Johnson Vision Announces Launch of TECNIS Eyhance™ Toric II IOL with TECNIS Simplicity™ Delivery System, a Next-Generation Monofocal Intraocular Lens for Cataracts Patients with Astigmatism, in Europe
TECNIS Eyhance™ Toric II IOL offers all the benefits associated with the TECNIS Eyhance™ IOL, such as high-quality intermediate and 20/20 distance vision1, whilst correcting patients’ astigmatism
More than 400 eyes from across 12 European countries have been fitted with the TECNIS Eyhance™ Toric II IOL so far, with surgeons surveyed stating that their patients were very satisfied with the lens2
June 8th, 2021 – Johnson & Johnson Vision,* a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies,** have announced the launch and availability of its TECNIS Eyhance™ Toric II intraocular lens (IOL) with TECNIS Simplicity™ Delivery System for the treatment of cataracts patients with astigmatism in Europe. This monofocal lens allows for high-quality vision at both intermediate and far distances1 and is specifically engineered for rotational stability.3
The TECNIS Eyhance™ Toric II IOL is the latest innovation in the industry-leading TECNIS® Family of IOLs. It allows patients to achieve significantly improved intermediate vision, compared with a standard aspheric monofocal IOL, along with 20/20 distance vision.1
“With the novel haptic design of the TECNIS Eyhance™ Toric II IOL along with excellent rotational stability, I have been able to offer my patients immediate improvements in their functional vision, while also correcting their astigmatism,” said Dr Filomena Ribeiro, Head Director of Ophthalmology, Hospital da Luz, Lisbon.*** “Having implanted the TECNIS Eyhance™ Toric II IOL, I can confidently say that this IOL is a game-changer in the monofocal category and in helping my patients get back to spending more time doing what they love.”
In a survey of 17 leading European ophthalmologists, who had early access to the TECNIS Eyhance™ Toric II IOL, all rated their patients as being very satisfied with the lens.2 Meanwhile, more than 79% perceived their patients as being very satisfied with their intermediate and distance vision.2 Additionally, 94% of those surveyed were very satisfied with the handling while implanting the lens, while nearly two thirds rated the overall performance of the lens as excellent compared to other toric IOLs.2 More than 80% also rated the rotational stability of the lens as excellent compared to other toric IOLs. All those surveyed said they were very likely to continue to use the lens in the future.2
“With this rollout of TECNIS Eyhance™ Toric II IOL, we are thrilled to extend the benefits of our most advanced monofocal IOL to cataract patients with astigmatism”, said Erin McEachren, Regional Vice President, EMEA, Johnson & Johnson Surgical Vision.**** “It’s an important first in Europe for the monofocal IOL category, as today most lenses in this category only correct vision to help patients with cataracts see things at a distance, and therefore don’t improve the intermediate vision that is required for many important daily tasks. This is another breakthrough in meeting the ever-changing and evolving needs of our patients across Europe and the world.”
Cataracts are the leading cause of blindness globally4 and, if left untreated, cause vision to deteriorate over time. Astigmatism reduces distance and near visual acuity, vision quality, and depth perception.5,6 In Europe, astigmatism affects over 50% of those over the age of 65, and over 20% of the population.7 Toric IOLs are the most common method for astigmatism correction in cataract patients.8
TECNIS Eyhance™ Toric II IOL is part of the TECNIS® Family of IOLs, which offer a variety of personalized vision options for people with cataracts, all with the goal of ensuring clear, sharp vision to meet individual needs and lifestyles. The TECNIS® IOL platform celebrated its 20th anniversary earlier this year.
About Cataracts and Presbyopia
Cataracts are the leading cause of blindness globally.9 More than 90 percent of people develop cataracts by age 65.9 If left untreated, cataracts cause vision to deteriorate over time. Cataract surgery is the most common surgery performed around the world,10 including more than 4 million times in the EU in 2016.11
Many people who have cataracts experience other problems with their vision, such as presbyopia. Cataract surgery is a unique opportunity to address presbyopia without an additional procedure. Presbyopia is a progressive eye condition, which makes it difficult to focus on close objects and usually becomes noticeable around 40 years of age.12
About Johnson & Johnson Vision*
At Johnson & Johnson Vision*, part of Johnson & Johnson Medical Devices Companies, we have a bold ambition: to change the trajectory of eye health worldwide. Through our operating companies, we deliver innovation that enables eye care professionals to create better outcomes for patients throughout their lives, with products and technologies that address unmet needs including refractive error, cataracts, and dry eye. In communities with greatest need, we work in collaboration to expand access to quality eye care, and we are committed to helping people see better, connect better, live better. Visit us at jjvision.com, follow @JNJVision on Twitter, Johnson & Johnson Vision on LinkedIn, and @JNJVision on Facebook.
About Johnson & Johnson Medical Devices Companies**
At Johnson & Johnson Medical Devices Companies, we are helping people live their best lives. Building on more than a century of expertise, we tackle pressing healthcare challenges, and take bold steps that lead to new standards of care while improving people’s healthcare experiences. In surgery, orthopaedics, vision, and interventional solutions, we are helping to save lives and paving the way to a healthier future for everyone, everywhere.
©Johnson & Johnson Vision Care Inc., 2021. All rights reserved.
1. DOF2018CT4015 – Clinical evaluation of the TECNIS Eyhance Model ICB00 – 6-month clinical study. Sep 2018. *Based on a clinical study, N=134 achieved mean 20/20 monocular pooled distance BCDVA.
2. TECNIS Eyhance™ Toric II IOL – Survey of 17 surgeons about experiences with DIU. May 2021. REF2021CT4156.
3. DOF2019OTH4015 - Study NXGT-103-MER3 - Proof of Concept Study for Next-Generation IOL Models MER003 and MER004. Aug. 28, 2019.
4. World Health Organization - Priority Eye Diseases. REF2016OTH0004.
5. Wolffsohn JS, et al. Effect of uncorrected astigmatism on vision. J Cataract Refract Surg 2011;37(3): 454-460. REF2018OTH5219.
6. Read SA, et al. The visual and functional impacts of astigmatism and its clinical management. Ophthalmic Physiol Opt 2014;34(3):267-294. REF2020OTH4615.
7. Williams KM, et al. Prevalence of refractive error in Europe: the European Eye Epidemiology (E(3)) Consortium. Eur J Epidemiol. 2015;30(4):305-315. doi:10.1007/s10654-015-0010-0. REF2020OTH4618.
8. Nunez MX, et al. Consensus on the management of astigmatism in cataract surgery. Clin Ophthalmol 2019;13:311-324. REF2019OTH4555.
9. University of Michigan Kellogg Eye Center website. http://www.kellogg.umich.edu/patientcare/conditions/cataract.html. Accessed November 2020. REF2016OTH0327
10. Trikha S, et al. The Journey to Femtosecond Laser-Assisted Cataract Surgery: New Beginnings or False Dawn? Eye 2013;27:461-473. REF2015OTH0014.
11. Eurostat - Surgical operations and procedures statistics. https://ec.europa.eu/eurostat/statistics- explained/index.php/Surgical_operations_and_procedures_statistics#In-patient_procedures: _cataract_surgery. Accessed April 2021. REF2018CT4377.
12. American Optometric Association. Presbyopia. American Optometric Association (AOA) Web site. https://www.aoa.org/patients-and-public/eye-and-vision-problems/glossary-of-eye-and-vision-conditions/presbyopia. Accessed April 2021. REF2019CT4316.